Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 25, 2022 07:00 ET | Source: ObsEva SA

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses

-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th...
May 25, 2022 01:00 ET | Source: ObsEva SA

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses

-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th...
December 10, 2021 01:00 ET | Source: ObsEva SA

ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

-Symposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10 at 1 p.m. CET- -52-Week Data from the Phase 3...
December 02, 2021 01:00 ET | Source: ObsEva SA

ObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

GENEVA, Switzerland December 2, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today...
November 02, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA hosts live symposium and presents oral communication at the SEUD Online Week November 3 - 6, 2020

Geneva, Switzerland and Boston, MA – 2 November, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve...